BBS-Bioactive Bone Substitutes (OHEL:BONEH) EBIT : €-3.39 Mil (TTM As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BBS-Bioactive Bone Substitutes EBIT?

BBS-Bioactive Bone Substitutes's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €-1.59 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €-3.39 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BBS-Bioactive Bone Substitutes's annualized ROC % for the quarter that ended in Jun. 2024 was -31.02%. BBS-Bioactive Bone Substitutes's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -362.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BBS-Bioactive Bone Substitutes's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -54.31%.

BBS-Bioactive Bone Substitutes EBIT Historical Data

The historical data trend for BBS-Bioactive Bone Substitutes's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BBS-Bioactive Bone Substitutes EBIT Chart

BBS-Bioactive Bone Substitutes Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-1.54

-2.65

-2.57

-2.95

-3.37

BBS-Bioactive Bone Substitutes Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial												-1.48	-1.47	-1.57	-1.79	-1.59

Competitive Comparison of BBS-Bioactive Bone Substitutes's EBIT

For the Medical Devices subindustry, BBS-Bioactive Bone Substitutes's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BBS-Bioactive Bone Substitutes's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BBS-Bioactive Bone Substitutes's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BBS-Bioactive Bone Substitutes's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

BBS-Bioactive Bone Substitutes EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-3.39 Mil.

BBS-Bioactive Bone Substitutes (OHEL:BONEH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BBS-Bioactive Bone Substitutes's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-3.182 * ( 1 - 0% )	/	( (9.732	+	10.783)	/ 2 )
=	-3.182	/	10.2575
=	-31.02 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.613	-	0.239	-	( 1.971	-	max(0, 1.377	-	2.019	+	1.971	))
=	9.732

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.374	-	0	-	( 0.85	-	max(0, 2.295	-	0.886	+	0.85	))
=	10.783

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

BBS-Bioactive Bone Substitutes's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.182	/	( ( (0.901 + max(-0.575, 0))	+	(0.821 + max(0.036, 0)) )	/	2 )
=	-3.182	/	( ( 0.901	+	0.857 )	/	2 )
=	-3.182	/	0.879
=	-362.00 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.239	+	0	+	0.336)
=	-0.575

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.039	+	0	+	-0.003)	-	(0	+	0	+	0)
=	0.036

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BBS-Bioactive Bone Substitutes's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-3.385	/	6.233
	=	-54.31 %

BBS-Bioactive Bone Substitutes EBIT Related Terms

Thank you for viewing the detailed overview of BBS-Bioactive Bone Substitutes's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BBS-Bioactive Bone Substitutes Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BBS-Bioactive Bone Substitutes PLC (OHEL:BONEH) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kiviharjunlenkki 6, Oulu, FIN, 90220

Website

https://www.bbs-artebone.fi

BBS-Bioactive Bone Substitutes PLC is a Finnish health technology company, that develops, designs and manufactures inventive bioactive bone-graft substitute implants. Its bioactive implants provide clinical and financial benefits for the treatment of patients with bone defects and healing problems.

BBS-Bioactive Bone Substitutes Headlines

No Headlines